News|Podcasts|November 16, 2026

Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense Freedom

Fact checked by: Ryan Livingston

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

The US Food and Drug Administration (FDA) cleared a tubeless cartridge and infusion set for the Tandem Mobi pump on November 12, 2026, adding a third US tubeless automated insulin delivery (AID) system.1 The infusion set is cleared for up to 7 days of wear, the longest of any tubeless AID system, while the cartridge is cleared for 3 days.1

On this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, also covered a continuous glucose monitor (CGM) formulary change and a transmitter-free implantable sensor.

The new supplies convert the existing Mobi pump rather than replacing it, so users can switch between tubed and tubeless wear on the same device.1 A patient could wear it tubeless on the arm in winter and switch to tubing at a less visible site in summer, a flexibility no competing system offers. Unlike Omnipod 5 and the Beta Bionics Mint, Mobi still requires daily charging.

The main draw is Control-IQ+, cleared for type 1 diabetes in patients aged 2 years and older, adults with type 2 diabetes, and pregnancy complicated by type 1 diabetes. In the 2IQP trial, Control-IQ+ lowered HbA1c by 0.9 percentage points in insulin-treated type 2 diabetes, vs 0.3 points with CGM alone (P < .001).2 In the CIRCUIT trial, pregnant participants using the system spent 65.4% of time in the pregnancy-specific range vs 50.3% with standard care (P < .001).3

Patients on high total daily insulin doses may need site rotation more often than every 7 days to keep absorption consistent and limit lipohypertrophy. Tandem expects a 2027 launch, with tubeless supplies available only through the pharmacy benefit, where Mobi coverage sits near 50%.

Access concerns extend to CGM. Some CVS Caremark and Aetna commercial formularies will switch from exclusive Dexcom to exclusive FreeStyle Libre coverage on January 1, 2027, a notable shift for Mobi users, since the pump pairs only with Dexcom.4 Some practices are issuing 90-day supplies before year end to buy time for prior authorizations.

Senseonics began a first-in-human study in October 2026 of Freedom, a 1-year implantable CGM designed to connect directly with a smartphone without the Eversense 365 on-body transmitter.5 A pivotal trial is planned for 2027, with a potential launch in 2028.5

Collectively, these developments show device makers competing on wear time, form factor, and flexibility, even as payer contracting increasingly shapes which devices reach patients.

References
  1. Tandem Diabetes Care. Tandem Mobi now FDA cleared as world's first and only tubeless AID system with up to seven days of wear. News release. November 13, 2026. Accessed November 16, 2026. https://stockhouse.com/news/press-releases/2026/11/13/tandem-mobi-now-fda-cleared-as-world-s-first-and-only-tubeless-aid-system-with
  2. Kudva YC, Raghinaru D, Lum JW, et al. A randomized trial of automated insulin delivery in type 2 diabetes. N Engl J Med. 2025;392(18):1801-1812. doi:10.1056/NEJMoa2415948
  3. Donovan LE, Lemieux P, Dunlop AD, et al. Closed-loop insulin delivery in type 1 diabetes in pregnancy: the CIRCUIT randomized clinical trial. JAMA. 2025;334(24):2176-2185. doi:10.1001/jama.2025.19578
  4. Dexcom. Information about potential 2027 coverage changes for some CVS Caremark and Aetna commercial members. Accessed November 16, 2026. https://www.dexcom.com/en-us/cvs-aetna
  5. Senseonics. Senseonics initiates first-in-human study of Freedom, designed to be the world's first CGM system with no on-body component. News release. October 26, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/10/26/3388017/0/en/index.html

Related to this article